Sensoria Analytics is looking for outlets for its cardiovascular disease prevention tool

[ad_1]

Cardiosensys consists of an oximeter and an application intended to "give the general practitioner an objective idea of ​​a person's cardiovascular state of health".

"Cardiovascular disease kills one in three people worldwide, and 50% of them have no symptoms," said Slah Aridhi in December. "When the doctors were asked why they were not doing more screening, they were unanimous: between the interview with the patient, the necessary analyzes and the study of the results, it takes far too long."

Sensoria Analytics has created an oximeter, "a familiar tool already present in the general practitioner's office", capable of detecting and studying seven vital signs: "heart rate, respiratory rate, oxygenation in the blood, elasticity arterial, arterial stiffness, heart variability and a blood pressure index. "

Measuring the respiratory rate "is difficult" and requires "a mask or a belt", but "with our algorithm, we get a good estimate just with the oximeter", argued the founder of the start-up.

The arterial stiffness and pressure measurements "directly display a green, yellow or red indicator". "We make a screening tool and not a diagnosis", the aim of which is "to help the doctor to know if he should send the patient to the cardiologist in emergency, without emergency" or not at all, he said. He insists.

The exam "can be done in one minute, but it is recommended to do it in two," said Slah Aridhi.

Cardiosensys is currently in the prototype stage, but "the heart of the technology is there".

The start-up has developed its own oximeter because "there are a lot of poor quality on the market today".

Clinical tests are planned at the Nice University Hospital in early 2020 "to increase its credibility", as well as "beta testing with many doctors" to assess its ergonomics.

Marketing "expected mid-2020"

The marketing of Cardiosensys is "hoped for mid-2020".

"Our first target is general practitioners in France and then in Europe", detailed the founder.

The objective of his participation in CES 2020: "meet integrating partners".

"There is interest from telemedicine players, who could integrate Cardiosensys into their booths or terminals rather than an ordinary oximeter, and from manufacturers of rehabilitation equipment or sleep apnea", detailed Slah Aridhi.

He also wants to "see American reactions to our solution and how it could integrate into their ecosystem", where "insurance and companies, which encourage patients to self-assess, could constitute B2C outlets".

The founder plans to launch a "family" fundraiser of 200,000 euros after the Las Vegas show to "launch the commercial phase". A second fundraiser is planned "for the expansion of the commercial strike force", to the tune of one million euros.

The start-up is today financed from the equity of its founder, with the help of BPIFrance and the Paca-Est incubator (Sophia-Antipolis) where it is hosted.

[ad_2]